|
Gene: TTL |
Gene summary for TTL |
Gene summary. |
Gene information | Species | Human | Gene symbol | TTL | Gene ID | 150465 |
Gene name | tubulin tyrosine ligase | |
Gene Alias | TTL | |
Cytomap | 2q14.1 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q8NG68 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
150465 | TTL | HCC1_Meng | Human | Liver | HCC | 2.30e-18 | 1.76e-02 | 0.0246 |
150465 | TTL | HCC2 | Human | Liver | HCC | 9.58e-20 | 3.89e+00 | 0.5341 |
150465 | TTL | Pt14.a | Human | Liver | HCC | 2.24e-03 | 2.59e-01 | 0.0169 |
150465 | TTL | S014 | Human | Liver | HCC | 1.02e-03 | 2.53e-01 | 0.2254 |
150465 | TTL | S016 | Human | Liver | HCC | 1.25e-02 | 1.97e-01 | 0.2243 |
150465 | TTL | S028 | Human | Liver | HCC | 1.53e-16 | 5.89e-01 | 0.2503 |
150465 | TTL | S029 | Human | Liver | HCC | 2.40e-10 | 5.72e-01 | 0.2581 |
150465 | TTL | C04 | Human | Oral cavity | OSCC | 1.01e-08 | 6.21e-01 | 0.2633 |
150465 | TTL | C21 | Human | Oral cavity | OSCC | 4.49e-08 | 3.48e-01 | 0.2678 |
150465 | TTL | C30 | Human | Oral cavity | OSCC | 6.89e-11 | 5.60e-01 | 0.3055 |
150465 | TTL | C38 | Human | Oral cavity | OSCC | 8.98e-05 | 5.37e-01 | 0.172 |
150465 | TTL | C46 | Human | Oral cavity | OSCC | 2.38e-02 | 1.46e-01 | 0.1673 |
150465 | TTL | C51 | Human | Oral cavity | OSCC | 8.78e-04 | 2.58e-01 | 0.2674 |
150465 | TTL | C09 | Human | Oral cavity | OSCC | 3.48e-02 | 9.74e-02 | 0.1431 |
150465 | TTL | SYSMH1 | Human | Oral cavity | OSCC | 5.30e-08 | 2.88e-01 | 0.1127 |
150465 | TTL | SYSMH2 | Human | Oral cavity | OSCC | 3.78e-09 | 3.36e-01 | 0.2326 |
150465 | TTL | SYSMH3 | Human | Oral cavity | OSCC | 3.60e-23 | 5.98e-01 | 0.2442 |
150465 | TTL | male-WTA | Human | Thyroid | PTC | 2.21e-14 | 1.64e-01 | 0.1037 |
150465 | TTL | PTC01 | Human | Thyroid | PTC | 1.95e-02 | 3.73e-02 | 0.1899 |
150465 | TTL | PTC04 | Human | Thyroid | PTC | 1.89e-05 | 1.61e-01 | 0.1927 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
GO:000641318 | Oral cavity | OSCC | translational initiation | 96/7305 | 118/18723 | 4.02e-21 | 7.06e-19 | 96 |
GO:000640118 | Oral cavity | OSCC | RNA catabolic process | 184/7305 | 278/18723 | 2.71e-20 | 4.19e-18 | 184 |
GO:005165610 | Oral cavity | OSCC | establishment of organelle localization | 239/7305 | 390/18723 | 2.46e-19 | 3.31e-17 | 239 |
GO:000640218 | Oral cavity | OSCC | mRNA catabolic process | 156/7305 | 232/18723 | 2.13e-18 | 2.37e-16 | 156 |
GO:000641720 | Oral cavity | OSCC | regulation of translation | 274/7305 | 468/18723 | 4.39e-18 | 4.63e-16 | 274 |
GO:003465517 | Oral cavity | OSCC | nucleobase-containing compound catabolic process | 244/7305 | 407/18723 | 5.38e-18 | 5.49e-16 | 244 |
GO:00073469 | Oral cavity | OSCC | regulation of mitotic cell cycle | 266/7305 | 457/18723 | 3.87e-17 | 3.41e-15 | 266 |
GO:004572719 | Oral cavity | OSCC | positive regulation of translation | 101/7305 | 136/18723 | 5.85e-17 | 4.94e-15 | 101 |
GO:004227420 | Oral cavity | OSCC | ribosomal small subunit biogenesis | 63/7305 | 73/18723 | 7.61e-17 | 6.34e-15 | 63 |
GO:003425019 | Oral cavity | OSCC | positive regulation of cellular amide metabolic process | 115/7305 | 162/18723 | 1.28e-16 | 1.05e-14 | 115 |
GO:004670015 | Oral cavity | OSCC | heterocycle catabolic process | 254/7305 | 445/18723 | 5.07e-15 | 3.31e-13 | 254 |
GO:00070592 | Oral cavity | OSCC | chromosome segregation | 206/7305 | 346/18723 | 5.82e-15 | 3.76e-13 | 206 |
GO:004427016 | Oral cavity | OSCC | cellular nitrogen compound catabolic process | 256/7305 | 451/18723 | 9.67e-15 | 5.88e-13 | 256 |
GO:001943915 | Oral cavity | OSCC | aromatic compound catabolic process | 263/7305 | 467/18723 | 1.49e-14 | 8.84e-13 | 263 |
GO:00064469 | Oral cavity | OSCC | regulation of translational initiation | 64/7305 | 79/18723 | 2.32e-14 | 1.30e-12 | 64 |
GO:001604917 | Oral cavity | OSCC | cell growth | 268/7305 | 482/18723 | 6.55e-14 | 3.51e-12 | 268 |
GO:00182056 | Oral cavity | OSCC | peptidyl-lysine modification | 216/7305 | 376/18723 | 2.32e-13 | 1.16e-11 | 216 |
GO:190136115 | Oral cavity | OSCC | organic cyclic compound catabolic process | 272/7305 | 495/18723 | 2.73e-13 | 1.36e-11 | 272 |
GO:00094114 | Oral cavity | OSCC | response to UV | 99/7305 | 149/18723 | 1.01e-11 | 3.70e-10 | 99 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TTL | SNV | Missense_Mutation | c.971N>G | p.Glu324Gly | p.E324G | Q8NG68 | protein_coding | tolerated(0.16) | benign(0.026) | TCGA-B6-A0IC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TTL | SNV | Missense_Mutation | novel | c.131G>T | p.Arg44Met | p.R44M | Q8NG68 | protein_coding | deleterious(0) | probably_damaging(0.909) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TTL | SNV | Missense_Mutation | novel | c.968A>G | p.Glu323Gly | p.E323G | Q8NG68 | protein_coding | deleterious(0.04) | benign(0.093) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TTL | SNV | Missense_Mutation | rs746535633 | c.279N>T | p.Trp93Cys | p.W93C | Q8NG68 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
TTL | SNV | Missense_Mutation | c.217N>T | p.Arg73Cys | p.R73C | Q8NG68 | protein_coding | deleterious(0) | probably_damaging(0.965) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TTL | SNV | Missense_Mutation | c.414G>T | p.Lys138Asn | p.K138N | Q8NG68 | protein_coding | tolerated(0.13) | benign(0.163) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TTL | SNV | Missense_Mutation | novel | c.661N>A | p.Leu221Ile | p.L221I | Q8NG68 | protein_coding | deleterious(0.03) | possibly_damaging(0.883) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TTL | SNV | Missense_Mutation | c.170N>T | p.Gly57Val | p.G57V | Q8NG68 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TTL | SNV | Missense_Mutation | c.679C>A | p.Pro227Thr | p.P227T | Q8NG68 | protein_coding | deleterious(0.02) | possibly_damaging(0.575) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TTL | SNV | Missense_Mutation | rs780073175 | c.218N>A | p.Arg73His | p.R73H | Q8NG68 | protein_coding | deleterious(0.02) | probably_damaging(0.925) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |